ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:ARIA
CUSIP04033A10
Phone+1-617-4940400
Debt
Debt-to-Equity Ratio-11.28
Current Ratio3.17
Quick Ratio3.15
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-60.47%
Return on EquityN/A
Return on Assets-17.16%
Miscellaneous
Employees459
Outstanding Shares194,390,000
Market Cap$0.00
Ariad Pharmaceuticals (NASDAQ:ARIA) Frequently Asked Questions
What is Ariad Pharmaceuticals' stock symbol?
Ariad Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARIA."
How were Ariad Pharmaceuticals' earnings last quarter?
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) released its quarterly earnings results on Thursday, July, 28th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.70. The pharmaceutical company had revenue of $65.30 million for the quarter, compared to the consensus estimate of $60.64 million. The business's revenue was up 133.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.28) EPS. View Ariad Pharmaceuticals' Earnings History.
How do I buy shares of Ariad Pharmaceuticals?
Shares of ARIA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ariad Pharmaceuticals' stock price today?
One share of ARIA stock can currently be purchased for approximately $23.99.
What is Ariad Pharmaceuticals' official website?
How can I contact Ariad Pharmaceuticals?
Ariad Pharmaceuticals' mailing address is 125 Binney St, CAMBRIDGE, MA 02142-1123, United States. The pharmaceutical company can be reached via phone at +1-617-4940400.
MarketBeat Community Rating for Ariad Pharmaceuticals (NASDAQ ARIA)
MarketBeat's community ratings are surveys of what our community members think about Ariad Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARIA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARIA will underperform the S&P 500 over the long term. You may vote once every thirty days.
